The positive findings from these preliminary studies support further evaluation of SR-BI-facilitated multi-targeted nanomedicines for cancer therapy, including complete characterization of particle biodistribution and therapeutic efficacy in orthotopic animal cancer models. Here, SCARB1 is linked to cancer.